Menu
Recruiting NCT06803108

Pyramidal Versus Continuous Training Effects on Fatty Liver

No phase Interventional Non-Alcoholic Fatty Liver Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: pyramidal activity program, aerobic activity program.
Who it may be relevant to
Registry conditions: Non-Alcoholic Fatty Liver Disease. Basic parameters: 37 years — 51 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

exercise is very important maneuver in the control of elevated liver enzymes in complaint of fatty liver .. the exercise forma are many.. from these exercises, pyramidal training or continues aerobic one.

Detailed description

the total participating subjects of the two groups of this study will be fatty liver subjects (19 subjects in every group). aerobic training on electronic treadmill will be adopted for 60 minutes in one group. In the other group, a pyramidal training will be adopted for nearly 60 minutes (nearly two rounds of 21 minutes of running on electronic treadmill will be separated with 10 minutes of rest between the two rounds. Also, warming (4 minutes before start of pyrimidal trianing) and cooling (4 minutes after pyramidal training) will be done through gentle stretching exercises/activities. the both forms of exercises will be done three times per week. the total study time will be 12 weeks. to be mentioned , the two groups followed low clorie diet

Interventions

  • Behavioral pyramidal activity program
    the participating subjects of this group of this study will be fatty liver subjects (19 subjects in this group). aerobic training on electronic treadmill will be adopted for 60 minutes in one group. In this group, a pyramidal training will be adopted for nearly 60 minutes (nearly two rounds of 21 minutes of running on electronic treadmill will be separated with 10 minutes of rest between the two rounds. Also, warming (4 minutes before start of pyrimidal trianing) and cooling (4 minutes after pyr
  • Behavioral aerobic activity program
    the participating subjects of the this group of this study will be fatty liver subjects (19 subjects in this group). aerobic training on electronic treadmill will be adopted for 60 minutes in this group with moderate intensity. the form of exercise will be done three times per week. the total study time will be 12 weeks. to be mentioned , this group will follow low clorie diet

Primary outcome measures

  • alanine transamianse [Time frame: it will be measured after 12 weeks]
Secondary outcome measures (7)
  • aspartate transaminase [Time frame: it will be measured after 12 weeks]
  • alkaline phosphatase [Time frame: it will be measured after 12 weeks]
  • Gamma-glutamyl transferase [Time frame: it will be measured after 12 weeks]
  • triglycerides [Time frame: it will be measured after 12 weeks]
  • high density lipoprotein [Time frame: it will be measured after 12 weeks]
  • body mass index [Time frame: It will be measured after 12 weeks]
  • waist circumference [Time frame: It will be measured after 12 weeks]

Eligibility criteria

Inclusion criteria

  • fatty liver patients
  • obese patients
  • all patients will class one obesity

Exclusion criteria

  • cardiovascular complaint
  • metabolic complaints
  • othopedic pains in lower limbs

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Cairo Unoversity — Giza

Identifiers

NCT: NCT06803108 · P.T.R.E.C/012/004669

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗